Episode 176: Elizabeth Holmes on trial, FDA in disarray, & the quest for Covid antivirals
Former Theranos CEO Elizabeth Holmes is finally headed to trial, and we discuss the case and why it might not be an open-and-shut conviction for prosecutors. Then, STAT Washington correspondent Nichol...
2 Syys 202133min
Episode 175: Dorit Reiss on vaccine mandates, plus biotech's messy summer
First, law professor Dorit Reiss joins us to discuss what the first FDA approval of a Covid-19 vaccine means for vaccination mandates and how this whole issue relates to jaywalking. Then we discuss bi...
26 Elo 202129min
Episode 174: Biotech's trust issues, overwhelmed health workers, & the nuances of insider trading
First, we discuss a sudden spike of FDA rejections, which has resurfaced a time-honored frustration: You can’t always trust biotech companies to be honest about their conversations with the agency. Th...
19 Elo 202128min
Episode 173: Biden's drug pricing plan, Wall Street's Alzheimer's fixation, & daily 5 a.m. alarms
First, STAT Washington correspondent Nicholas Florko joins us to explain President Biden's proposal to lower drug prices, how it might affect the 2022 election, and why there's still no nominee for FD...
12 Elo 202130min
Episode 172: The mRNA gold rush, Delta's alarming rise, & the next treatment for Alzheimer's
First, we dive into the potential of mRNA, a technology that proved itself with Covid-19 vaccines and is now seeding a pharmaceutical gold rush. Then, STAT's Helen Branswell joins us to discuss the st...
5 Elo 202133min
Episode 171: The quest for a Covid pill, a microbiome gut-check, & CRISPR on the big screen
First, we discuss the CDC's about-face on mask wearing, the debate over vaccine booster shots, and the slow but steady race to develop pills for Covid-19. Then, STAT's Kate Sheridan joins us to discus...
29 Heinä 202134min
Episode 170: Céline Gounder on breakthrough infections, plus the power of lobbying
First, Céline Gounder of NYU’s Grossman School of Medicine joins us to discuss the issue of breakthrough coronavirus infections and whether the U.S. was too quick to unmask. Then, STAT's Rachel Cohrs ...
22 Heinä 202132min
Episode 169: Dan Diamond on covering Biden, plus the FDA's future, & the latest Aduhelm twist
First, we'll talk about the future of the FDA, whose acting commissioner will have to step down in November unless she’s given the permanent job. Next, Washington Post reporter Dan Diamond joins us to...
15 Heinä 202130min
